PT-141 (Bremelanotide) Research Guide: Mechanism of Action, Clinical Studies & Scientific Review
Shop Our Top Compounds
PT-141 (Bremelanotide) Research Guide: Mechanism of Action, Clinical Studies & Scientific Review
PT-141 (Bremelanotide) Research Guide: Mechanism of Action, Clinical Studies & Scientific Review
All information presented in this article is for research and educational purposes only. PT-141 (bremelanotide) peptides sold by Iron Peak Peptides are intended strictly for in-vitro research and laboratory use. Not for human consumption.
Introduction: What Is PT-141 and Why Does It Matter for Research?
PT-141 research has emerged as one of the most compelling areas of investigation in modern peptide science. Known by its pharmaceutical name bremelanotide, PT-141 is a synthetic cyclic heptapeptide and a synthetic peptide that acts as a melanocortin receptor agonist — specifically targeting the MC3R and MC4R receptor subtypes expressed primarily in the central nervous system (CNS). Unlike conventional compounds that act on the vascular system, PT-141 research has demonstrated that this peptide operates through a fundamentally different neurological pathway, modulating dopamine release in key hypothalamic regions.
Originally derived from Melanotan II research at the University of Arizona, the bremelanotide peptide has been the subject of extensive preclinical and clinical investigation. Its unique mechanism of action — activating CNS melanocortin receptors rather than peripheral vascular pathways — has positioned it as a groundbreaking subject in neuropharmacology. Unlike traditional erectile dysfunction medications that primarily increase blood flow to the penis, bremelanotide works by stimulating the brain’s centers for sexual response, thereby boosting sexual desire. In 2019, the U.S. Food and Drug Administration (FDA) approved bremelanotide (marketed as Vyleesi®) for premenopausal women with hypoactive sexual desire disorder (HSDD), making it the first melanocortin-based therapy to receive regulatory approval for this indication.
This comprehensive PT-141 research guide examines the published scientific literature, clinical trial data, pharmacokinetics, safety profiles, and emerging research directions surrounding this fascinating melanocortin peptide. Whether investigating melanocortin receptor signaling, dopaminergic neurotransmission, or CNS-mediated physiological responses, researchers will find PT-141 to be an invaluable tool for laboratory investigation. Sexual function is an integral part of overall well-being, and PT-141 research contributes to a holistic understanding of sexual health. For those looking to source research-grade peptides, Shop PT-141 is available through Iron Peak Peptides’ catalog.
—
The History and Development of PT-141: From Melanotan II to Bremelanotide
The Discovery of Melanocortin Peptides
The story of PT-141 research begins with the broader investigation of melanocortin peptides — a family of endogenous neuropeptides derived from proopiomelanocortin (POMC). In the early 1990s, researchers at the University of Arizona, led by Dr. Victor Hruby and colleagues, were developing synthetic analogs of alpha-melanocyte stimulating hormone (α-MSH) to study skin pigmentation and tanning responses. Their work produced Melanotan II, a potent synthetic cyclic analog of α-MSH with broad melanocortin receptor activity.
During early clinical studies of Melanotan II, an unexpected observation changed the course of peptide research: male subjects reported spontaneous erectile responses following subcutaneous administration. This serendipitous finding, first documented by Wessells et al. (1998), revealed that melanocortin receptor activation in the CNS could produce profound physiological effects on sexual function — a mechanism entirely independent of the vascular pathways targeted by existing compounds.
From Melanotan II to PT-141
Recognizing the therapeutic potential of this CNS-mediated mechanism, Palatin Technologies developed PT-141 (bremelanotide) as a more targeted derivative of Melanotan II. Structurally, PT-141 is a cyclic lactam heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It was designed to retain the melanocortin receptor agonist properties relevant to sexual function research while minimizing off-target effects associated with the parent compound.
The key structural difference between Melanotan II and PT-141 lies in the removal of the C-terminal amide, which reduces MC1R-mediated tanning effects while preserving robust MC3R and MC4R activity. This refinement made the PT-141 peptide a more selective research tool for studying CNS melanocortin signaling pathways. For researchers interested in comparing these two melanocortin peptides, the Melanotan II Research Guide provides detailed analysis of the parent compound.
—
PT-141 Mechanism of Action: How Bremelanotide Works at the Molecular Level
Melanocortin Receptor Subtypes and CNS Expression
Understanding the PT-141 mechanism of action requires familiarity with the melanocortin receptor system. There are five known melanocortin receptor subtypes (MC1R–MC5R), each with distinct tissue distribution and physiological roles. PT-141 research has established the following receptor binding profile, in order of potency: MC1R > MC4R > MC3R > MC5R > MC2R (DrugBank, 2023).
For the purposes of PT-141 research related to CNS-mediated effects, the MC4R and MC3R subtypes are the most pharmacologically relevant:
MC4R (Melanocortin-4 Receptor): Predominantly expressed in the hypothalamus, specifically the medial preoptic area (mPOA), paraventricular nucleus (PVN), and ventromedial hypothalamus. Research has demonstrated that MC4R activation is critical for modulating sexual function, appetite regulation, and energy homeostasis.
MC3R (Melanocortin-3 Receptor): Expressed in the arcuate nucleus of the hypothalamus and other CNS regions. MC3R functions as an inhibitory autoreceptor on POMC neurons and plays a modulatory role in energy balance and neuroendocrine signaling.
The Dopaminergic Mechanism
Published research has elucidated a detailed neurobiological model for how bremelanotide produces its effects. According to the comprehensive review by Clayton et al. (2021), the proposed mechanism proceeds as follows:
Receptor Binding: Following systemic administration, bremelanotide crosses into the CNS and binds to presynaptic MC4R receptors on neurons within the mPOA of the hypothalamus.
Dopamine Release: MC4R activation on these neurons stimulates the release of dopamine (DA), a key excitatory neurotransmitter in the sexual response pathway.
Downstream Signaling: Increased dopaminergic transmission in the mPOA activates descending neural pathways that modulate autonomic and somatic responses related to sexual function.
Hypothalamic Integration: The mPOA serves as an integration center, receiving inputs from cortical, limbic, and hormonal systems. MC4R-mediated dopamine release within this region may shift the excitatory/inhibitory balance toward excitation.
This CNS-mediated mechanism fundamentally distinguishes the PT-141 peptide from PDE5 inhibitors (such as sildenafil), which act peripherally on vascular smooth muscle. Research by Molinoff et al. (2003) demonstrated that systemic administration of PT-141 in rats activated hypothalamic neurons, as evidenced by increased c-Fos immunoreactivity in the PVN — the same region implicated in neural tracing studies using pseudorabies virus injected into the corpus cavernosum.
Central vs. Peripheral Mechanisms: PT-141 and PDE5 Inhibitors
One of the most significant findings in PT-141 research is the demonstration that bremelanotide operates through an entirely different pharmacological pathway compared to PDE5 inhibitors. This distinction has been confirmed in multiple studies:
Feature | PT-141 (Bremelanotide) | PDE5 Inhibitors (e.g., Sildenafil) |
|---|---|---|
Primary Target | MC3R/MC4R in CNS | PDE5 enzyme in vascular tissue |
Mechanism | Dopamine release in hypothalamus | Increased cGMP / smooth muscle relaxation |
Action Site | Central nervous system | Peripheral vasculature |
Requires Stimulation | Variable (study-dependent) | Typically requires sexual stimulation |
Route Studied | Subcutaneous injection | Oral administration |
Research by Rosen et al. (2004) demonstrated that PT-141 produced statistically significant erectile responses in subjects who reported inadequate responses to 100 mg sildenafil, suggesting the two compounds act through complementary and non-overlapping mechanisms. This finding has major implications for researchers studying the neurobiology of sexual function. For a broader comparison of peptide research compounds, visit our Peptide Comparison Chart.
—
Published Clinical Research and Trial Data
Early-Phase Clinical Studies in Male Subjects
The earliest PT-141 research in human subjects established dose-response relationships and confirmed the melanocortin-mediated erectile mechanism observed in animal models.
Phase I/II Dose-Ranging Study (Rosen et al., 2004):
In a landmark study, PT-141 was administered subcutaneously to healthy male subjects (0.3–10 mg) and to subjects with erectile dysfunction (4 and 6 mg) in a crossover design. Erectile responses, measured by RigiScan monitoring, were statistically significant at doses greater than 1.0 mg in healthy subjects. In subjects with ED — including those with inadequate response to sildenafil — both 4 mg and 6 mg doses produced statistically significant erectile responses compared to placebo.
Intranasal Pharmacodynamic Study (Diamond et al., 2004):
A double-blind, placebo-controlled study evaluated intranasal PT-141 in healthy males and subjects with mild-to-moderate ED. The study confirmed dose-dependent erectogenic responses and established the pharmacodynamic profile of the intranasal formulation, though subsequent development focused on subcutaneous administration.
Combination Research (Diamond et al., 2005):
Research published in the International Journal of Impotence Research evaluated co-administration of subtherapeutic doses of intranasal PT-141 with sildenafil. The study observed an enhanced erectile response with combination treatment, supporting the hypothesis that CNS melanocortin and peripheral PDE5 pathways are complementary.
Phase III RECONNECT Clinical Trials
The most robust PT-141 research data comes from the RECONNECT Phase III clinical trial program — two identical, randomized, double-blind, placebo-controlled, multicenter studies that evaluated bremelanotide 1.75 mg administered subcutaneously as needed.
Study Design (Kingsberg et al., 2019):
1,267 premenopausal women randomized 1:1 to bremelanotide or placebo
24-week treatment period
Co-primary endpoints: Female Sexual Function Index-desire domain (FSFI-D) score and Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13
Key Findings:
Research subjects receiving bremelanotide demonstrated statistically significant increases in desire scores compared to placebo (Study 301: +0.30, P<.001; Study 302: +0.42, P<.001; integrated: +0.35, P<.001)
Statistically significant reductions in desire-related distress were observed (Study 301: -0.37, P<.001; Study 302: -0.29, P=.005; integrated: -0.33, P<.001)
The safety profile was characterized as favorable, with most treatment-emergent adverse events being mild or moderate
Long-Term Safety and Efficacy Data
The long-term profile of bremelanotide was evaluated in an open-label extension study (Kingsberg et al., 2019b). Research subjects who completed the core 24-week RECONNECT studies were eligible to continue treatment for up to an additional 52 weeks.
Key Long-Term Findings:
Sustained improvements in HSDD symptoms were maintained throughout the extension period
No new safety signals emerged with prolonged administration
The tolerability profile remained consistent with the core study data
Researchers noted that treatment-emergent adverse events decreased over time, suggesting potential habituation to tolerability-related effects
Phase 2b Dose-Ranging Research
A Phase 2b dose-ranging study (Althof et al., 2019) provided important data on the dose-response relationship of bremelanotide. The study evaluated multiple dose levels and demonstrated that bremelanotide was safe, well-tolerated, and produced significant efficacy improvements versus placebo, supporting the selection of the 1.75 mg subcutaneous dose for Phase III investigation.
—
Pharmacokinetics and Administration in Research Models
Absorption and Distribution
Published pharmacokinetic research on the PT-141 peptide has characterized its absorption and distribution profile following subcutaneous administration:
Peak Plasma Concentration (Tmax): Research has demonstrated that following subcutaneous injection, bremelanotide reaches peak plasma concentrations within approximately 1 hour (Tmax ≈ 0.5–1.0 hour)
Mean Cmax: At the 1.75 mg clinical dose, the mean maximum plasma concentration reaches approximately 72.8 ng/mL
Bioavailability: Subcutaneous administration provides reliable systemic exposure with consistent absorption kinetics
Distribution: Bremelanotide demonstrates CNS penetration, as evidenced by its central pharmacological effects and neuronal activation patterns observed in preclinical imaging studies
Metabolism and Elimination
Half-life: The terminal elimination half-life of bremelanotide is approximately 2.7 hours
Metabolism: Research indicates that bremelanotide undergoes hydrolysis to multiple metabolites; it is not a significant substrate of major CYP450 enzymes, reducing the potential for metabolic drug interactions in research protocols
Excretion: The compound is eliminated through both renal and hepatic pathways
Research Administration Considerations
In published studies, researchers administered bremelanotide via subcutaneous injection. The pharmacokinetic profile supports an as-needed administration paradigm rather than daily dosing, with the onset of pharmacological effects observed within 30–60 minutes and duration of measurable plasma levels extending several hours. For researchers sourcing PT-141 for laboratory investigation, Shop PT-141 at Iron Peak Peptides offers research-grade peptides.
—
Safety Profile: Adverse Events Documented in Clinical Research
Commonly Reported Adverse Events
Across the PT-141 research program, the most frequently documented treatment-emergent adverse events included:
Nausea as the Primary Tolerability Concern
Research has consistently identified nausea as the most common adverse event associated with bremelanotide administration. In the RECONNECT Phase III trials, approximately 40% of subjects in the bremelanotide group reported nausea compared to approximately 1% in the placebo group. Importantly, published data indicates that:
The majority of nausea episodes were mild to moderate in severity
Nausea incidence decreased with repeated administration over the course of the study
Discontinuation rates due to nausea were relatively low
Cardiovascular Considerations
PT-141 research has documented small, transient increases in blood pressure following administration. Dedicated ambulatory blood pressure monitoring studies evaluated this effect and found:
Mean increases in systolic blood pressure of approximately 2–3 mmHg
Effects were self-limiting and resolved within hours
No clinically significant cardiovascular events were attributed to bremelanotide in the clinical trial program
Melanin and Pigmentation
Due to its melanocortin receptor activity (particularly MC1R), researchers have investigated potential effects on skin pigmentation. The RECONNECT trials included dermatologic assessments, and focal hyperpigmentation (darkening of small skin areas) was observed in a small percentage of research subjects receiving bremelanotide.
—
Regulatory Status and FDA Approval
The Path to Approval
In June 2019, the FDA approved bremelanotide injection (Vyleesi®) for the treatment of acquired, generalized HSDD in premenopausal women. This approval was based on the RECONNECT Phase III clinical trial program data. Key regulatory milestones included:
2004–2008: Phase I/II clinical studies in male and female subjects
2014–2016: RECONNECT Phase III trial enrollment and completion
2019: FDA approval of Vyleesi® (bremelanotide 1.75 mg subcutaneous injection)
Approved Indication
The FDA-approved indication is specifically for acquired, generalized HSDD in premenopausal women. The prescribing information notes it is not indicated for enhancement of sexual performance and includes limitations on use (no more than one dose within 24 hours and no more than 8 doses per month).
Research vs. Clinical Use
It is important for researchers to distinguish between the FDA-approved pharmaceutical product (Vyleesi®) and research-grade PT-141 peptides available for laboratory investigation. Research-grade PT-141, such as that available at Iron Peak Peptides, is intended solely for in-vitro research and laboratory use. Browse All Peptides to explore IronPeak’s complete research catalog.
—
Emerging Research Directions: Beyond Sexual Function
Melanocortin Receptors and Appetite Regulation
One of the most active areas of emerging PT-141 research involves the melanocortin system’s well-established role in appetite regulation and energy homeostasis. MC4R is a critical regulator of food intake and body weight, and loss-of-function mutations in MC4R are the most common monogenic cause of obesity in humans.
While bremelanotide itself was not advanced as an anti-obesity agent, the broader melanocortin pathway research it has stimulated continues to yield insights. The FDA approval of setmelanotide (Imcivree®) in 2020 — a more selective MC4R agonist — for genetic obesity conditions validated the therapeutic potential of melanocortin-based approaches to metabolic research.
Anti-Inflammatory and Neuroprotective Pathways
Research has demonstrated that melanocortin peptides, including compounds structurally related to bremelanotide, exhibit anti-inflammatory properties mediated through MC3R and MC4R activation. Preclinical studies have shown that melanocortin receptor agonism can:
Reduce pro-inflammatory cytokine production
Modulate microglial activation in the CNS
Attenuate neuroinflammatory responses in animal models of brain injury
These findings suggest that PT-141 and related melanocortin peptides may serve as valuable research tools for investigating neuroimmune signaling pathways.
Pain Modulation Research
MC4R receptors are expressed in CNS regions involved in pain processing, including the periaqueductal gray (PAG) and spinal cord dorsal horn. Published research has demonstrated that MC4R signaling modulates nociceptive pathways, with melanocortin agonists showing potential to influence pain perception in preclinical models. This represents an emerging and potentially high-impact direction for melanocortin peptide research.
Peptide Stacking in Research Protocols
Some researchers have investigated the use of multiple peptides in combined research protocols to study synergistic or complementary mechanisms. The Peptide Stacking Research Guide provides an overview of published multi-peptide research approaches and the scientific rationale behind combination investigations.
—
Published Research Citations
The following peer-reviewed studies form the scientific foundation of this PT-141 research guide:
1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Annals of the New York Academy of Sciences, 994, 96-102, 2003. DOI: 10.1111/j.1749-6632.2003.tb03167.x
2. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. “Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.” Journal of Urology, 160(2), 389-393, 1998. PMID: 9679884
3. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. “Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.” International Journal of Impotence Research, 16(2), 135-142, 2004. DOI: 10.1038/sj.ijir.3901200
4. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. “Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.” International Journal of Impotence Research, 16(1), 51-59, 2004. DOI: 10.1038/sj.ijir.3901139
5. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. “Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.” International Journal of Impotence Research, 17(4), 317-324, 2005. DOI: 10.1038/sj.ijir.3901330
6. Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. “Melanocortins in the treatment of male and female sexual dysfunction.” Current Topics in Medicinal Chemistry, 7(11), 1137-1144, 2007. DOI: 10.2174/156802607780906681
7. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. “Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials.” Obstetrics & Gynecology, 134(5), 899-908, 2019. DOI: 10.1097/AOG.0000000000003500
8. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. “Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder.” Obstetrics & Gynecology, 134(5), 909-917, 2019. DOI: 10.1097/AOG.0000000000003501
9. Clayton AH, Lucas J, Jordan R, Spana C, Sadiq A, Krop J, Kimura T. “The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.” CNS Spectrums, 26(6), 629-636, 2021. DOI: 10.1017/S109285292100002X
10. Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J, Spana C. “Responder analyses from a phase 2b dose-ranging study of bremelanotide.” Journal of Sexual Medicine, 16(8), 1226-1235, 2019. DOI: 10.1016/j.jsxm.2019.05.012
11. Mayer D, Lynch SE. “Bremelanotide: New drug approved for treating hypoactive sexual desire disorder.” Annals of Pharmacotherapy, 54(7), 684-690, 2020. DOI: 10.1177/1060028019899152
12. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. “Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.” Proceedings of the National Academy of Sciences, 101(27), 10201-10204, 2004. DOI: 10.1073/pnas.0400491101
13. Giuliano F. “Control of penile erection by the melanocortinergic system: experimental evidences and therapeutic perspectives.” Journal of Andrology, 25(5), 683-691, 2004. DOI: 10.1002/j.1939-4640.2004.tb02842.x
14. Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, Vanderah TW. “MT-II induces penile erection via brain and spinal mechanisms.” Annals of the New York Academy of Sciences, 994, 90-95, 2003. DOI: 10.1111/j.1749-6632.2003.tb03166.x
—
Frequently Asked Questions About PT-141 Research
What is PT-141 (bremelanotide) and how does it differ from other peptides?
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide classified as a melanocortin receptor agonist. It was derived from the earlier research compound Melanotan II and is structurally designed to activate MC3R and MC4R receptors in the central nervous system. Unlike many other research peptides that act on peripheral tissues, PT-141 research has demonstrated that bremelanotide exerts its primary effects through CNS dopaminergic pathways in the hypothalamus. This makes it a unique research tool for investigating central neuroendocrine signaling. Visit our Peptide Glossary for definitions of key terms.
How does the PT-141 mechanism of action differ from PDE5 inhibitors?
The PT-141 mechanism of action is fundamentally different from PDE5 inhibitors such as sildenafil. While PDE5 inhibitors work by blocking the phosphodiesterase-5 enzyme in vascular smooth muscle to increase blood flow (a peripheral mechanism), bremelanotide research has demonstrated that PT-141 acts centrally in the brain by activating melanocortin-4 receptors in the hypothalamus. This activation leads to increased dopamine release in the medial preoptic area, modulating sexual response through a CNS-mediated pathway. Published studies have confirmed that PT-141 produced significant responses in research subjects who reported inadequate responses to PDE5 inhibitors, confirming the non-overlapping nature of these mechanisms.
What were the key findings from the RECONNECT Phase III clinical trials?
The RECONNECT trials were two identical Phase III, randomized, double-blind, placebo-controlled studies that evaluated bremelanotide 1.75 mg administered subcutaneously in 1,267 premenopausal women with HSDD. Research demonstrated statistically significant improvements in sexual desire scores (integrated FSFI-D improvement of +0.35, P<.001) and statistically significant reductions in desire-related distress (integrated FSDS-DAO improvement of -0.33, P<.001) compared to placebo. The safety profile was favorable, with nausea, flushing, and headache as the most commonly reported adverse events.
What adverse events have been documented in PT-141 research?
Across published clinical studies, the most frequently reported adverse events in bremelanotide research subjects were nausea (approximately 40%), flushing (approximately 20%), headache (approximately 11%), and injection site reactions. The majority of adverse events were mild to moderate in severity. Research has also documented small, transient increases in blood pressure that resolved without intervention. Nausea incidence was observed to decrease with repeated administration over time.
Is PT-141 FDA-approved?
Yes, bremelanotide was approved by the FDA in June 2019 under the brand name Vyleesi® for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as a 1.75 mg subcutaneous injection on an as-needed basis. It is important to note that research-grade PT-141 peptides, such as those available from Iron Peak Peptides, are intended solely for in-vitro research and laboratory use and are distinct from the commercial pharmaceutical product.
How is PT-141 related to Melanotan II?
PT-141 (bremelanotide) was derived from Melanotan II through structural modification. Both are synthetic melanocortin peptides, but PT-141 was specifically designed to reduce MC1R-mediated pigmentation effects while preserving MC3R/MC4R activity relevant to CNS-mediated physiological research. Melanotan II is a linear precursor that retains broader melanocortin receptor activity. The Melanotan II Research Guide provides a detailed comparison of the two compounds.
What are the emerging research directions for melanocortin peptides like PT-141?
Current research directions for melanocortin peptides extend well beyond the initial sexual function investigations. Published studies have explored MC3R/MC4R roles in appetite regulation and energy homeostasis, anti-inflammatory and neuroprotective pathways, and pain modulation through MC4R signaling in the periaqueductal gray and spinal cord. The FDA approval of setmelanotide (a selective MC4R agonist) for genetic obesity in 2020 further validated the therapeutic potential of the melanocortin system, and ongoing research continues to investigate novel applications.
Where can researchers source PT-141 for laboratory investigation?
Iron Peak Peptides offers research-grade PT-141 for in-vitro and laboratory research purposes. All peptides undergo rigorous quality testing to ensure purity and consistency for research applications. Shop PT-141 or Browse All Peptides to explore the complete catalog of research compounds available.
—
Conclusion: The Significance of PT-141 Research in Modern Peptide Science
PT-141 research represents a paradigm shift in our understanding of CNS-mediated physiological pathways. As a melanocortin receptor agonist that operates through hypothalamic dopaminergic mechanisms rather than peripheral vascular targets, bremelanotide has opened entirely new avenues of investigation in neuropharmacology, neuroendocrinology, and peptide science.
The published clinical data — spanning Phase I through Phase III trials and long-term extension studies — provides a robust scientific foundation for understanding melanocortin receptor signaling. The RECONNECT trials, with their large sample sizes and rigorous double-blind, placebo-controlled designs, represent some of the most comprehensive peptide research programs ever conducted. The subsequent FDA approval of bremelanotide as Vyleesi® validated the melanocortin approach and catalyzed further research into MC3R and MC4R pathways across multiple therapeutic domains.
For researchers investigating melanocortin receptor biology, dopaminergic neurotransmission, CNS peptide signaling, or the expanding frontier of melanocortin applications in inflammation, metabolism, and nociception, PT-141 remains an essential research tool. Importantly, PT-141 bremelanotide research is offering hope to individuals with sexual dysfunction and related conditions by expanding treatment possibilities. Iron Peak Peptides is committed to providing the highest-quality research-grade peptides to support these important scientific investigations. Shop PT-141 or explore the full research peptide catalog today.
Research Disclaimer
The information in this article is provided for educational and research purposes only. PT-141 (bremelanotide) and all peptides available through Iron Peak Peptides are intended exclusively for in-vitro research and laboratory use. These products are not intended for human consumption and are not to be used as food, drugs, or cosmetics. No claims are made regarding therapeutic efficacy for any condition. Researchers should consult all applicable regulations in their jurisdiction before conducting research with peptide compounds. The content of this article does not constitute medical advice, and nothing herein should be interpreted as a recommendation for diagnosis, treatment, or prevention of any disease. All research citations refer to published peer-reviewed literature and do not imply endorsement of any commercial product.
Related Research
🔬 Explore Research Peptides
- IPP-3 RT — Price range: $89.00 through $173.00
- IPP-1 ELO — $70.00
- TB-500 10mg — $69.99
- B12 10mg — $55.00
